A subgroup of these patients does not develop pathologic complete response despite the fact that this subtype has initial responsiveness to chemotherapy.
Small cell lung cancer (SCLC) is a distinct clinicopathologic entity characterized by neuroendocrine differentiation, early metastatic spread, and initial responsiveness to cytotoxic therapy.
Despite initial responsiveness to combined carboplatin and paclitaxel chemotherapy, most patients develop chemoresistant tumors and ultimately succumb to the recurrent disease [2].
Despite rapid and robust initial responsiveness to TRAIL, surviving cells quickly acquired resistance to the additional TRAIL treatment.
Despite initial responsiveness to the chemotherapeutic drugs, most patients eventually develop chemoresistance and succumb to their diseases [ 1, 2].
The clinical definition of the disease is based on the core features listed above and includes initial responsiveness to levodopa.
3 Initial responsiveness to cisplatin therapy is high; however, the majority of patients ultimately relapse with resistant disease.
However, this initial responsiveness to hormones is transient as reduced UGT1A expression correlated with a significant reduction in patient survival (P=0.025, Log-rank analysis; Figure 4E).
These two disparate observations might be reconciled if the increased initial responsiveness to sulfonylureas shown by carriers of the risk allele evolves into β-cell exhaustion and earlier sulfonylurea failure, but such hypotheses require longer term follow-up.
Follicular lymphoma (FL) is the most common type of indolent B-cell lymphoma, accounting for 10 20% of all malignant lymphomas (MLs) 1. FL is characterized by frequent relapses and progression to treatment-resistant disease or transformation to high-grade feature, despite initial responsiveness to chemotherapy or radiotherapy 2, 3.
